| Title |
Rucaparib: First Global Approval
|
|---|---|
| Published in |
Drugs, March 2017
|
| DOI | 10.1007/s40265-017-0716-2 |
| Pubmed ID | |
| Authors |
Yahiya Y. Syed |
| Abstract |
Rucaparib (Rubraca™) is an oral, small molecule, poly (ADP-ribose) polymerase inhibitor being developed by Clovis Oncology, Inc. (Boulder, CO, USA) for the treatment of solid tumours. It has been approved in the USA as monotherapy for the treatment of patients with deleterious BRCA mutation (germline and/or somatic) associated advanced ovarian cancer who have been treated with two or more chemotherapies. A marketing authorization application for rucaparib for the same indication has been submitted to the European Medicines Agency. Rucaparib is also under phase II or III investigation in ovarian, breast and prostate cancer. This article summarizes the milestones in the development of rucaparib leading to this first approval for ovarian cancer. |
X Demographics
The data shown below were collected from the profiles of 2 X users who shared this research output. Click here to find out more about how the information was compiled.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| Colombia | 1 | 50% |
| Poland | 1 | 50% |
Demographic breakdown
| Type | Count | As % |
|---|---|---|
| Members of the public | 1 | 50% |
| Scientists | 1 | 50% |
Mendeley readers
The data shown below were compiled from readership statistics for 49 Mendeley readers of this research output. Click here to see the associated Mendeley record.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| Unknown | 49 | 100% |
Demographic breakdown
| Readers by professional status | Count | As % |
|---|---|---|
| Student > Master | 10 | 20% |
| Student > Ph. D. Student | 10 | 20% |
| Student > Bachelor | 7 | 14% |
| Researcher | 4 | 8% |
| Student > Doctoral Student | 3 | 6% |
| Other | 5 | 10% |
| Unknown | 10 | 20% |
| Readers by discipline | Count | As % |
|---|---|---|
| Biochemistry, Genetics and Molecular Biology | 12 | 24% |
| Medicine and Dentistry | 7 | 14% |
| Chemistry | 6 | 12% |
| Pharmacology, Toxicology and Pharmaceutical Science | 5 | 10% |
| Agricultural and Biological Sciences | 4 | 8% |
| Other | 3 | 6% |
| Unknown | 12 | 24% |
Attention Score in Context
This research output has an Altmetric Attention Score of 5. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 10 May 2022.
All research outputs
#6,338,572
of 22,963,381 outputs
Outputs from Drugs
#1,089
of 3,283 outputs
Outputs of similar age
#103,585
of 311,232 outputs
Outputs of similar age from Drugs
#23
of 44 outputs
Altmetric has tracked 22,963,381 research outputs across all sources so far. This one has received more attention than most of these and is in the 72nd percentile.
So far Altmetric has tracked 3,283 research outputs from this source. They typically receive a little more attention than average, with a mean Attention Score of 7.0. This one has gotten more attention than average, scoring higher than 66% of its peers.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 311,232 tracked outputs that were published within six weeks on either side of this one in any source. This one has gotten more attention than average, scoring higher than 66% of its contemporaries.
We're also able to compare this research output to 44 others from the same source and published within six weeks on either side of this one. This one is in the 47th percentile – i.e., 47% of its contemporaries scored the same or lower than it.